Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer

OBJECTIVE: Galunisertib (LY2157299 monohydrate), an inhibitor of the transforming growth factor β (TGFβ) pathway, is currently under investigation in several clinical trials involving multiple tumor types. The primary objective of this study was to assess relative bioavailability of two new galunise...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Drugs Context
Hlavní autoři: Gueorguieva, Ivelina, Cleverly, Ann, Desaiah, Durisala, Azaro, Analia, Seoane, Joan, Braña, Irene, Sicart, Elisabet, Miles, Colin, Lahn, Michael M, Mitchell, Malcolm I, Rodon, Jordi
Médium: Artigo
Jazyk:Inglês
Vydáno: Just Medical Media Limited 2016
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5147053/
https://ncbi.nlm.nih.gov/pubmed/27990167
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.212303
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky